National Minority Vaccination Program Likely To Be Cost-Effective

Published Mar 17, 2013
Pittsburgh, PA, USA - Invasive pneumococcal disease (IPD) is a major cause of hospitalizations and death in the elderly population. Despite the widespread availability of an effective vaccine against IPD, vaccination rates in the elderly minority population remain low.  A national vaccination program to increase the number of elderly minorities receiving a widely recommended vaccine that prevents a serious form of pneumonia would likely be cost effective. In the study, “Cost-Effectiveness of a Program to Eliminate Disparities in Pneumococcal Vaccination Rates in Elderly Minority Populations: An Exploratory Analysis,” published in Value in Health, researchers at the University of Pittsburgh School of Medicine used a mathematical decision analysis model to predict the cost-effectiveness of a future national vaccination program to increase vaccination rates in elderly minorities. The results of this decision analysis model suggest that a national vaccination program to increase the number of elderly minorities receiving the vaccine against IPD would be cost-effective, preventing 853 hospitalizations and 134 deaths due to IPD over the lifetime of the 65 year old minority cohort in the United States. Kenneth J. Smith, MD, MS, from the University of Pittsburgh School of Medicine, and lead author on the study, states, “"Underserved minority seniors receive pneumococcal vaccine less than seniors of other races, which is a serious problem. Our research suggests that these vaccination disparities can be overcome in an economically reasonable way."

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.

Advancing the Economics of Mental Health: A Global Perspective

Mar 12, 2025

Value in Health, the official journal of ISPOR announced the publication of a special themed section of research papers exploring mental health economics, highlighting impacts on caregivers, productivity, and interventions’ cost-effectiveness.

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×